Comparison of Intravascular Versus Intramuscular Betamethasone Phosphate on Neonatal Outcomes in the Cases of Imminent Preterm Birth

Kashanian, Maryam; Eshraghi, Nooshin; Kalani, Majid; Bordbar, Arash; Eshraghi, Nasim; Kalati, Mahnaz; Norouzi, Sara; Kashanian, Amir Hossein

doi:10.30699/jogcr.9.2.125

Document Type : Original Research Article

Authors

¹ Department of Obstetrics and Gynecology, Akbarabadi Teaching Hospital, Iran University of Medical Sciences, Tehran, Iran

² Department of Pediatrics (Neonatology), Akbarabadi Teaching Hospital, Iran University of Medical Science, Tehran, Iran

³ Department of Medicine, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

⁴ Department of Nursing, School of Nursing and Midwifery, Iran University of Medical Sciences, Tehran, Iran

⁵ Department of Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

https://doi.org/10.30699/jogcr.9.2.125

Abstract

Background & Objective: Preterm birth is the most important cause of neonatal mortality and morbidity. Finding the best treatment regimen, of antenatal corticosteroids, has been under serious concern. To compare the efficacy of intravascular versus intramuscular betamethasone phosphate on neonatal outcomes in the cases of imminent preterm birth.
Materials & Methods: A double-blind randomized clinical trial was performed on 136 eligible pregnant women with gestational age of 26- 34 weeks and imminent preterm birth (delivery within 24 hours). They were randomly assigned into two groups. Group A received intramuscular betamethasone phosphate, and group B received a similar dose of betamethasone phosphate intravenously. Women were followed up to delivery, and their neonatal outcomes were compared.
Results: Women of the two groups (68 women in each group), did not show a significant difference in maternal age, BMI, gravidity and parity, gestational age at the time of admission and delivery, history of miscarriage and assisted reproductive techniques, delivery route, sex and weight of newborns, and Apgar score in minutes 1 and 5. The need for NICU admission, duration of hospitalization, neonatal respiratory distress syndrome, surfactant requirement, and intubation were lower in the IV betamethasone group. There were no significant differences between the two groups according to necrotizing enterocolitis, intraventricular hemorrhage, and neonatal death.
Conclusion: Using IV betamethasone, in cases where there is no enough time to complete the 24-hour betamethasone course due to the possibility of impending delivery, may reduce neonatal complications due to quicker onset of action.

Keywords

Main Subjects

Maternal Fetal Medicine

References

1. Kashanian M, Shirvani S, Sheikhansari N, Javanmanesh F. A comparative study on the efficacy of nifedipine and indomethacin for prevention of preterm birth as monotherapy and combination therapy: a randomized clinical trial. J Matern-Fetal Neonatal Med. 2020;33(19):3215-20. [DOI:10.1080/14767058.2019.1570117] [PMID]

2. García-Basteiro AL, Quintó L, Macete E, Bardají A, González R, Nhacolo A, et al. Infant mortality and morbidity associated with preterm and small-for-gestational-age births in Southern Mozambique: A retrospective cohort study. PLoS One. 2017;12(2):e0172533. [DOI:10.1371/journal.pone.0172533] [PMID] [PMCID]

3. Manuck TA, Rice MM, Bailit JL, Grobman WA, Reddy UM, Wapner RJ, et al. Preterm neonatal morbidity and mortality by gestational age: a contemporary cohort. BMC Pregnancy Childbirth. 2016;215(1):103.e1-.e14.

4. Guo X, Li X, Qi T, Pan Z, Zhu X, Wang H, et al. A birth population-based survey of preterm morbidity and mortality by gestational age. BMC Pregnancy Childbirth. 2021;21:1-12. [DOI:10.1186/s12884-021-03726-4] [PMID] [PMCID]

5. Chen R, Sjölander A, Johansson S, Lu D, Razaz N, Tedroff K, et al. Impact of gestational age on risk of cerebral palsy: unravelling the role of neonatal morbidity. Int J Epidemiol. 2021;50(6):1852-63. [DOI:10.1093/ije/dyab131] [PMID] [PMCID]

6. Crowley P, Roberts D, Dalziel SR, Shaw BNJ. Antenatal corticosteroids to accelerate fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2003;3(3):CD004454. [DOI:10.1002/14651858.CD004454]

7. Brownfoot FC, Gagliardi DI, Bain E, Middleton P, Crowther CA. Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2013;8(8):CD006764. [DOI:10.1002/14651858.CD006764.pub3] [PMID]

8. Olaloko O, Mohammed R, Ojha U. Evaluating the use of corticosteroids in preventing and treating bronchopulmonary dysplasia in preterm neonates. Int J Gen Med. 2018;11(null):265-74. [DOI:10.2147/IJGM.S158184] [PMID] [PMCID]

9. Bahadori F, Fakour Z, Redaei R, Khalkhali HR, Sahebazzamani Z. The Effect of Betamethasone on the Consequences of Late Preterm Pregnancy: A Double-Blind Randomized Clinical Trial. J Obstet Gynecol Cancer Res. 2021;6(1):10-5. [DOI:10.30699/jogcr.6.1.10]

10. Bahl R, Gülmezoglu AM, Nguyen MH, Oladapo OT, Piaggio G, Vogel JP, et al. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries. Trials. 2019;20(1):507. [DOI:10.1186/s13063-019-3488-z] [PMID] [PMCID]

11. Sebastian E, Bykersma C, Eggleston A, Eddy KE, Chim ST, Zahroh RI, et al. Cost-effectiveness of antenatal corticosteroids and tocolytic agents in the management of preterm birth: A systematic review. EClinicalMedicine. 2022;49:101496. [DOI:10.1016/j.eclinm.2022.101496] [PMID] [PMCID]

12. Rohwer AC, Oladapo OT, Hofmeyr GJ. Strategies for optimising antenatal corticosteroid administration for women with anticipated preterm birth. Cochrane Database of Systematic Reviews. 2020(5). [DOI:10.1002/14651858.CD013633] [PMID] [PMCID]

13. Kashanian M, Eshraghi N, Sheikhansari N, Bordbar A, Khatami E. Comparison between two doses of betamethasone administration with 12 hours vs. 24 hours intervals on prevention of respiratory distress syndrome: a randomised trial. Obstet Gynecol. 2018;38(6):770-6. [DOI:10.1080/01443615.2017.1413080] [PMID]

14. Khandelwal M, Chang E, Hansen C, Hunter K, Milcarek B. Betamethasone dosing interval: 12 or 24 hours apart? A randomized, noninferiority open trial. Am J Obstet Gynecol. 2012;206(3):201.e1-.e11. [DOI:10.1016/j.ajog.2012.01.025] [PMID]

15. Haas DM, Haas DM, McCullough W, McNamara MF, Olsen C. The first 48 hours: Comparing 12-hour and 24-hour betamethasone dosing when preterm deliveries occur rapidly. J Matern-Fetal Neonatal Med. 2006;19(6):365-9. [DOI:10.1080/14767050600715873] [PMID]

16. Thevathasan I, Said JM. Controversies in antenatal corticosteroid treatment. Prenat Diagn. 2020;40(9):1138-49. [DOI:10.1002/pd.5664] [PMID]

17. Lee MJ, Debra G. Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery. Available from: [https://www.uptodate.com/contents/antenatal-corticosteroid-therapy-for-reduction-of-neonatal-respira]

18. Petersen MC, Ashley JJ, McBride WG, Nation RL. Disposition of betamethasone in parturient women after intramuscular administration. Br J Clin Pharmacol. 1984;18(3):383-92. [DOI:10.1111/j.1365-2125.1984.tb02480.x] [PMID] [PMCID]

19. Petersen MC, Nation RL, McBride WG, Ashley JJ, Moore RG. Pharmacokinetics of betamethasone in healthy adults after intravenous administration. Eur J Clin Pharmacol. 1983;25(5):643-50. [DOI:10.1007/BF00542353] [PMID]

20. Petersen MC, Collier CB, Ashley JJ, McBride WG, Nation RL. Disposition of betamethasone in parturient women after intravenous administration. Eur J Clin Pharmacol. 1983;25(6):803-10. [DOI:10.1007/BF00542524] [PMID]

21. Elimian A, Figueroa R, Spitzer AR, Ogburn PL, Wiencek V, Quirk JG. Antenatal corticosteroids: are incomplete courses beneficial? Obstet Gynecol. 2003;102(2):352-5. [DOI:10.1097/00006250-200308000-00025] [DOI:10.1016/S0029-7844(03)00485-X] [PMID]

22. Schmidt AF, Kemp MW, Kannan PS, Kramer BW, Newnham JP, Kallapur SG, et al. Antenatal dexamethasone vs. betamethasone dosing for lung maturation in fetal sheep. Pediatr Res. 2017;81(3):496-503. [DOI:10.1038/pr.2016.249] [PMID]

23. Crowther CA, Ashwood P, Andersen CC, Middleton PF, Tran T, Doyle LW, et al. Maternal intramuscular dexamethasone versus betamethasone before preterm birth (ASTEROID): a multicentre, double-blind, randomised controlled trial. Lancet Child Adolesc Health. 2019;3(11):769-80. [DOI:10.1016/S2352-4642(19)30292-5] [PMID]

24. Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2017;3(3):CD004454. [DOI:10.1002/14651858.CD004454.pub3] [PMID] [PMCID]

25. Jobe AH, Kemp M, Schmidt A, Takahashi T, Newnham J, Milad M. Antenatal corticosteroids: a reappraisal of the drug formulation and dose. Pediatr Res. 2021;89(2):318-25. [DOI:10.1038/s41390-020-01249-w] [PMID] [PMCID]

Journal of Obstetrics, Gynecology and Cancer Research

Comparison of Intravascular Versus Intramuscular Betamethasone Phosphate on Neonatal Outcomes in the Cases of Imminent Preterm Birth

References

References

Volume 9, Issue 2 - Serial Number 37
March and April 2024
Pages 125-130

Comparison of Intravascular Versus Intramuscular Betamethasone Phosphate on Neonatal Outcomes in the Cases of Imminent Preterm Birth

References

References

Volume 9, Issue 2 - Serial Number 37March and April 2024Pages 125-130

Volume 9, Issue 2 - Serial Number 37
March and April 2024
Pages 125-130